Best for Anti-Inflammation

GLP-1 receptor agonists demonstrate consistent anti-inflammatory effects across multiple human studies and meta-analysis, with significant reductions in key inflammatory markers (CRP, TNF-α, IL-6, IL-1β) and mechanistic evidence supporting these effects. Efficacy is proven in humans but evidence is primarily from observational studies and one large meta-analysis rather than multiple large RCTs.

Zinc supplementation demonstrates consistent, clinically meaningful reductions in inflammatory markers (CRP, IL-6, TNF-α) across multiple human trials and meta-analyses. Evidence is strong but limited by modest sample sizes in individual RCTs and heterogeneity in dosing protocols.

Berberine demonstrates strong evidence for reducing inflammatory markers in humans through multiple meta-analyses of randomized controlled trials. Consistent reductions in IL-6, TNF-α, and CRP across diverse metabolic conditions establish proven efficacy, though optimal dosing and long-term effects require further clarification.

Curcumin has strong, consistent evidence demonstrating anti-inflammatory efficacy in humans across multiple randomized controlled trials and meta-analyses. Multiple large meta-analyses confirm significant reductions in inflammatory markers (CRP, TNF-α, IL-6) and clinical improvements in inflammatory conditions.

Resveratrol demonstrates strong evidence for reducing inflammatory markers (TNF-α, CRP) in humans across multiple RCTs and meta-analyses, with consistent effect sizes. However, efficacy is primarily demonstrated in specific populations (diabetes, obesity, multiple sclerosis) rather than as a universal anti-inflammatory agent.

Melatonin supplementation has strong evidence for reducing multiple inflammatory markers in humans, particularly C-reactive protein, TNF-α, and IL-6, with consistent results across multiple meta-analyses and clinical trials. Efficacy is proven in humans with clinically meaningful effect sizes, though studies remain primarily in disease-specific populations (diabetes, metabolic syndrome, multiple sclerosis).

Spirulina demonstrates consistent anti-inflammatory effects across multiple human RCTs and meta-analyses, with significant reductions in key inflammatory markers (IL-6, TNF-α, CRP, IL-1β). Evidence is strong but limited by heterogeneous dosing, variable study durations, and moderate sample sizes.

Boswellia serrata demonstrates strong efficacy for reducing inflammation and osteoarthritis symptoms in humans, supported by multiple RCTs showing consistent pain reduction, improved joint function, and decreased inflammatory biomarkers. Clinical effects are clinically meaningful and replicated across independent studies.

Tirzepatide significantly reduces inflammatory markers (hsCRP and IL-6) in humans with consistent effects across multiple randomized controlled trials. Evidence is strong but limited to short-term studies (≤52 weeks) with modest sample sizes.

Dulaglutide reduces multiple inflammatory biomarkers (CRP, TNF-α, IL-6) in humans with type 2 diabetes and metabolic conditions. Evidence comes from multiple human RCTs and observational studies showing consistent, clinically meaningful reductions in inflammation-related markers.

Creatine monohydrate shows mixed effects on inflammation markers in human studies, with some evidence of benefit after acute exercise but no consistent effect on chronic inflammatory biomarkers. Most rigorous meta-analyses report null findings for CRP and IL-6.

Ashwagandha demonstrates probable efficacy for reducing inflammation and inflammatory markers in humans, supported by multiple RCTs showing consistent reductions in C-reactive protein, inflammatory cytokines, and oxidative stress markers. However, most human studies are small (n<100), short-duration (30-84 days), and lack long-term safety data, preventing a higher evidence tier.

Thymosin alpha-1 reduces inflammatory markers and modulates immune function in sepsis and severe infections, but a large phase 3 RCT failed to demonstrate mortality benefit. Evidence for inflammation reduction is moderate and fairly consistent across studies, though clinical significance remains unclear.

Tesamorelin reduces inflammation and immune activation markers in HIV patients with fatty liver disease, demonstrated across multiple human RCTs. However, efficacy is limited to specific inflammatory proteins; broader clinical anti-inflammatory benefits remain modest and inconsistently measured.

Melanotan 1 (afamelanotide), an α-MSH analogue, demonstrates anti-inflammatory effects in multiple small human studies for dermatologic conditions, but evidence remains limited to pilot RCTs and small case series without large-scale replication or meta-analytic confirmation.

Thymalin shows probable efficacy for reducing inflammation across multiple human studies, with consistent improvements in inflammatory markers and immune parameters. However, evidence is limited by small sample sizes, lack of placebo controls in most studies, and absence of large-scale RCTs with standardized dosing.

ARA-290 shows probable anti-inflammatory efficacy in humans based on 2-3 small RCTs and multiple animal studies, but evidence is limited by small sample sizes, short treatment durations, and lack of independent replication in large-scale clinical trials.

Cerebrolysin demonstrates probable anti-inflammatory efficacy in multiple human studies and consistent effects across animal models of neuroinflammation, but evidence remains limited by small sample sizes, heterogeneous clinical conditions, and lack of large-scale RCTs specifically powered for inflammation outcomes.

Prostatilen demonstrates probable anti-inflammatory efficacy in human observational studies of prostatitis and pyelonephritis, with consistent reporting of reduced inflammatory markers and clinical symptom relief. However, evidence is limited to uncontrolled observational trials without placebo controls or randomization, and no human RCTs exist to confirm efficacy.

Cortexin shows probable efficacy for reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in human neurological conditions, demonstrated in 2 RCTs and 1 observational study. However, evidence remains limited by small sample sizes, lack of independent replication, and inconsistent effect sizes across studies.

Omega-3 fatty acids demonstrate probable anti-inflammatory efficacy in humans, with multiple RCTs and meta-analyses showing reductions in inflammatory markers like CRP and IL-6, though effect sizes are modest and results are inconsistent across inflammatory cytokines.

Magnesium supplementation shows probable but inconsistent effects on inflammatory markers in humans. Meta-analyses report reductions in CRP and some cytokines, but individual RCTs show mixed results with many null findings, particularly for IL-6 and TNF-α in general populations.

NAC demonstrates anti-inflammatory effects in multiple human and animal studies, with consistent reductions in pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) across diverse inflammatory conditions. However, human evidence remains limited to small RCTs and observational studies; the largest human RCT (n=14) showed NAC increased GSH but failed to suppress TNF-α production in vivo despite in vitro efficacy.

Vitamin D3 shows probable anti-inflammatory effects in humans based on multiple RCTs and observational studies, but evidence is mixed with modest effect sizes and considerable heterogeneity. Some well-designed trials demonstrate clinically meaningful reductions in inflammatory markers, while others show null results.

Quercetin shows probable but inconsistent anti-inflammatory effects in humans, with some meta-analyses demonstrating modest reductions in specific inflammatory markers (particularly CRP) at doses ≥500 mg/day, but multiple RCTs report null findings for other cytokines and inflammatory outcomes.

CoQ10 shows probable efficacy for reducing inflammation markers in humans, with multiple RCTs and meta-analyses demonstrating reductions in TNF-α, IL-6, and CRP. However, effects are modest and inconsistent across inflammatory markers, and clinical meaningfulness remains unclear.

Alpha-lipoic acid demonstrates probable efficacy for reducing inflammatory markers (CRP, IL-6, TNF-α) in humans based on multiple RCTs and meta-analyses, though effect sizes are modest and results are inconsistent across patient populations.

Collagen peptides show probable efficacy for reducing inflammation-related symptoms in osteoarthritis and other inflammatory conditions based on 5 human RCTs, but evidence is limited by small sample sizes, short-term follow-up, and inconsistent inflammatory biomarker findings.

Probiotics demonstrate probable efficacy in reducing inflammation markers across multiple human studies, but effects are modest, inconsistently measured across different inflammatory markers, and often lack independent replication. Evidence quality is moderate with several well-designed RCTs, but many studies are small and use different probiotic strains, making generalization difficult.

Vitamin K2 shows probable anti-inflammatory effects in humans based on multiple RCTs, but evidence is limited by small sample sizes, inconsistent markers measured across studies, and mixed results in some outcomes. Most rigorous evidence comes from studies of specific populations (Long COVID, Type 2 diabetes, postmenopausal women) rather than inflammation as a primary endpoint.

Boron supplementation shows probable anti-inflammatory effects based on one human RCT demonstrating reduced menstrual pain and multiple animal studies showing decreased inflammatory markers. However, evidence in humans is limited to a single small trial, and most data come from animal models.

Rhodiola rosea demonstrates probable efficacy for reducing inflammation through multiple mechanistic pathways, supported by consistent findings in animal studies and emerging human evidence. However, human RCT evidence specifically for inflammation as a primary outcome remains limited, preventing a higher tier classification.

Black seed oil shows probable anti-inflammatory effects supported by two human RCTs and extensive mechanistic animal/in-vitro data, but efficacy remains incompletely proven due to small sample sizes and limited independent replication in humans.

Aged Garlic Extract (AGE) demonstrates probable efficacy in reducing inflammatory markers, particularly C-reactive protein (CRP) and TNF-α, based on multiple human RCTs and meta-analyses. However, evidence quality is limited by small sample sizes, inconsistent effects on some markers (e.g., IL-6), and short study durations.

Saw palmetto (Serenoa repens) demonstrates anti-inflammatory effects in prostate tissue with evidence from multiple human studies and mechanistic research, but efficacy for general inflammation remains incompletely established. Most evidence focuses on prostatic inflammation in the context of BPH and prostatitis rather than systemic inflammation.

Fenugreek demonstrates probable anti-inflammatory efficacy supported by multiple animal studies and limited human evidence, but robust large-scale human RCTs are lacking. Animal research consistently shows reduction in inflammatory markers (TNF-α, IL-6, IL-1β), but human clinical proof remains limited to 2 small RCTs.

Glucosamine + chondroitin shows modest efficacy for knee osteoarthritis pain and function in multiple RCTs, but results are inconsistent and effect sizes are clinically small. Evidence is moderate quality with mixed findings across studies.

Vitamin C shows probable anti-inflammatory efficacy in humans based on multiple RCTs and observational studies, particularly in acute surgical/sepsis settings. However, results are inconsistent across conditions, effect sizes vary widely, and the highest-quality sepsis trials were terminated or underpowered.

Vitamin B12 supplementation shows probable benefit for reducing inflammation markers in several human studies, particularly in combination with folate, but evidence remains limited by small sample sizes, short durations, and inconsistent clinical outcomes across different conditions.

Vitamin E supplementation shows modest anti-inflammatory effects in humans, particularly for reducing C-reactive protein (CRP) levels, but efficacy is inconsistent across inflammatory biomarkers and clinical conditions. Evidence is limited to small human trials and meta-analyses with significant heterogeneity.

Selenium supplementation shows probable but not conclusive benefits for reducing inflammation, with most evidence from meta-analyses of small RCTs and observational studies. Results are mixed: some inflammatory markers (IL-6, pain scores) improve, while others (CRP, TNF-α) show inconsistent or non-significant effects.

Chromium supplementation shows probable efficacy for reducing inflammatory markers in humans with metabolic disorders, particularly PCOS and type 2 diabetes, but evidence is limited by small sample sizes, short durations, and inconsistent effect sizes across studies.

Biotin supplementation reduces inflammatory markers and cytokine production in both animal models and limited human studies, with effects on immune cell proliferation and NF-κB signaling. However, efficacy is supported primarily by small human trials and animal studies rather than large, independently-replicated RCTs.

Spermidine demonstrates plausible anti-inflammatory effects through autophagy induction across multiple animal and observational studies, with one human RCT showing cognitive benefits but limited direct inflammation biomarker measurement in humans.

Urolithin A demonstrates probable anti-inflammatory efficacy in humans based on 3 RCTs and multiple observational studies, with consistent reductions in inflammatory markers (CRP, cytokines) and improvements in immune parameters. However, evidence remains moderate due to small sample sizes (n=20-50), short intervention periods (4-8 weeks), and limited independent replication across different research groups.

Sulforaphane demonstrates anti-inflammatory effects through NRF2 pathway activation in multiple human and animal studies, but clinical efficacy remains probable rather than proven due to limited high-quality RCTs and mixed results in key patient populations.

Astaxanthin shows modest anti-inflammatory effects in humans with type 2 diabetes and cardiovascular conditions, but efficacy is inconsistent across populations and outcomes. Multiple human RCTs demonstrate some benefit, but effect sizes are small and results do not replicate uniformly.

Glutathione supplementation shows probable anti-inflammatory effects in humans based on multiple small RCTs and observational studies, with evidence of reduced pro-inflammatory cytokines (TNF-α, IL-6, IL-1α) in specific conditions. However, efficacy is not conclusively proven, as several studies showed non-significant trends or null results, and most human trials were small (n<50) with short durations.

Pycnogenol shows probable anti-inflammatory efficacy in humans based on multiple small-to-moderate RCTs and observational studies, with consistent reductions in inflammatory biomarkers (IL-6, MMP-8) and clinical symptoms across several conditions. However, evidence remains limited by small sample sizes, short durations, and lack of independent replication by research groups outside the primary study networks.

TUDCA shows probable anti-inflammatory efficacy in humans with ulcerative colitis and in animal models of various inflammatory conditions, but evidence remains limited to one small open-label RCT in humans and multiple animal studies. Clinical efficacy is plausible but not yet conclusively proven.

Beta-glucans show probable anti-inflammatory efficacy in humans based on one RCT and several observational studies, but the evidence remains limited. A double-blind RCT demonstrated reduced pro-inflammatory cytokine markers after exercise-induced inflammation, and multiple mechanistic studies confirm effects on inflammasome inhibition and macrophage reprogramming, but large-scale human trials are lacking.

Cordyceps shows probable anti-inflammatory effects in humans and animals, with two small RCTs and mechanistic evidence supporting efficacy, but human studies remain limited in size and sample diversity. Multiple animal models and in-vitro studies consistently demonstrate inflammatory pathway suppression, but clinical significance in humans requires larger, longer-duration trials.

Reishi demonstrates probable anti-inflammatory efficacy in humans and animals through multiple mechanisms, but evidence is limited to 1 small RCT and 1 observational study; most data come from animal models and mechanistic in-vitro work rather than definitive human trials.

Pterostilbene demonstrates probable efficacy in reducing inflammation across multiple human and animal studies, with two human RCTs showing measurable improvements in liver inflammation markers and inflammatory cytokines. However, evidence remains limited by small sample sizes, short durations, and inconsistent dose-response patterns.

Pomegranate extract demonstrates probable anti-inflammatory efficacy in humans, with multiple RCTs showing reductions in inflammatory markers (IL-6, IL-1β, CRP) and disease activity in conditions like rheumatoid arthritis and obesity-related inflammation. However, sample sizes are modest (n=30-86), study duration is short (4-12 weeks), and results show inconsistent clinical significance across markers.

Grape seed extract demonstrates probable anti-inflammatory efficacy in humans based on multiple small-to-moderate RCTs showing reductions in inflammatory markers (hs-CRP, TNF-α, IL-6), but evidence is limited by small sample sizes, short study durations, and lack of large-scale replication.

MSM shows modest benefits for knee osteoarthritis pain and inflammation-related outcomes in multiple human RCTs, but evidence is mixed with several negative trials and small-to-moderate effect sizes. Efficacy is probable but not conclusive, particularly for mild-to-moderate OA.

Bromelain shows probable anti-inflammatory efficacy in humans based on multiple small RCTs and observational studies, with consistent reductions in inflammatory markers and pain/swelling in acute conditions. However, evidence is limited by small sample sizes, short study durations, and mixed results in some applications.

Lactoferrin shows probable efficacy for reducing inflammation-related infections in preterm infants and children, with consistent reductions in late-onset sepsis and diarrhea across multiple RCTs. However, evidence for systemic anti-inflammatory effects in healthy adults is limited and inconsistent.

Tribulus terrestris shows probable anti-inflammatory effects in human studies with consistent reductions in inflammatory markers (IL-6, CRP) following exercise, but sample sizes are small (n=13-34) and results lack independent replication. Efficacy is plausible but not conclusively proven.

Echinacea shows probable anti-inflammatory and immunomodulatory effects in humans, with consistent evidence from multiple RCTs and observational studies demonstrating reduced respiratory symptoms and altered cytokine profiles. However, effect sizes are modest, sample sizes are small (n<100), and clinical meaningfulness remains unclear.

Lemon balm shows probable efficacy for reducing inflammation in humans, supported by 2 well-designed RCTs demonstrating significant reductions in inflammatory markers (hs-CRP, MDA) and improvements in lipid profiles in diabetic and cardiovascular disease populations. However, evidence is limited by small sample sizes and lack of independent replication.

Methylene blue shows probable efficacy for reducing inflammation and improving hemodynamic outcomes in septic shock and vasoplegic conditions in humans, supported by 4 RCTs and multiple observational studies. However, evidence is limited by small sample sizes, heterogeneous dosing regimens, and lack of replication across independent research centers.

Rapamycin demonstrates probable efficacy for reducing inflammation across multiple human studies and numerous animal models, with consistent effects on inflammatory pathways and clinical outcomes. However, evidence remains limited by small human sample sizes, short treatment durations, and lack of large-scale RCTs, preventing definitive proof of clinical efficacy.

Astragalus shows probable anti-inflammatory effects supported by multiple human studies and meta-analyses, with consistent reductions in pro-inflammatory cytokines and improvements in immune markers. However, evidence remains limited by small sample sizes, heterogeneity across studies, and lack of large-scale RCTs with standardized dosing.

Hyaluronic acid demonstrates probable efficacy for reducing inflammation and joint pain in osteoarthritis patients based on multiple human RCTs, but evidence is limited by small sample sizes, short study durations, and lack of independent replication across research groups.

Butyrate shows probable anti-inflammatory effects supported by multiple human studies and consistent animal data, but efficacy remains incompletely proven due to limited high-quality RCTs, small sample sizes, and inconsistent mechanistic findings across inflammatory contexts.

Peppermint oil demonstrates probable efficacy for reducing IBS-related gastrointestinal symptoms and abdominal pain in humans, supported by multiple clinical trials and consistent recommendations in international guidelines. However, evidence remains limited to a small number of human studies with modest sample sizes and short durations, preventing a higher tier classification.

Ginkgo biloba extract reduces inflammatory markers (CRP, IL-6, TNF-α) in human clinical trials with statistically significant effects, but evidence is limited to small-to-moderate sample sizes and short durations. Efficacy is probable but not conclusively proven.

Vinpocetine demonstrates anti-inflammatory effects across multiple human and animal studies, primarily through NF-κB and PDE1 inhibition. However, efficacy is supported mainly by observational human studies and animal models; only 3 human RCTs exist, and clinical meaningfulness remains incompletely characterized.

Oxiracetam demonstrates probable anti-inflammatory efficacy in human and animal models of neurological conditions, with consistent reductions in inflammatory markers across multiple studies. However, efficacy is not conclusively proven due to small sample sizes, lack of placebo controls in some studies, and confounding combination therapies.

Acetyl-L-carnitine (ALC) shows probable efficacy for reducing inflammation across multiple human and animal studies, with consistent mechanistic support and positive clinical outcomes in specific conditions like fibromyalgia and inflammatory bowel disease, but evidence remains limited by small sample sizes and lack of large-scale replication.

Glycine shows probable anti-inflammatory effects in humans based on observational data and mechanistic studies, but high-quality human RCT evidence is sparse. Most evidence comes from animal models and mechanistic reviews demonstrating NF-κB modulation and immune effects.

Beta-alanine shows modest anti-inflammatory effects in humans during intense physical stress, with reductions in CRP and IL-6 observed in athletic populations. However, efficacy is inconsistent across contexts, and evidence is limited to small RCTs with mixed results.

HMB supplementation shows probable efficacy for reducing inflammation markers in specific contexts (cardiac surgery, military training, COPD), with multiple human RCTs demonstrating reduced TNF-α, IL-6, and CRP levels. However, evidence remains moderate due to small sample sizes, heterogeneous populations, and inconsistent findings across different inflammatory markers.

Taurine demonstrates probable efficacy for reducing inflammation in humans based on multiple RCTs and meta-analyses, with consistent reductions in key inflammatory markers like CRP and MDA. However, evidence is limited by small sample sizes, short intervention periods, and mixed results on some inflammatory cytokines (TNF-α, IL-6).

L-Carnosine demonstrates anti-inflammatory and antioxidant effects supported by one human RCT showing reductions in TNF-α and other inflammatory markers in type 2 diabetes patients. However, efficacy remains probable but not conclusive due to limited human trial data, small sample sizes, and lack of independent replication.

Retatrutide shows probable efficacy for reducing inflammation in metabolic and hepatic disease models, with consistent anti-inflammatory effects demonstrated across multiple animal studies and emerging human evidence. However, human proof of concept remains limited to observational data and meta-analyses; only one human RCT design document exists without outcome data.

Larazotide shows probable efficacy for reducing inflammation in specific conditions (celiac disease, MIS-C) by restoring intestinal barrier integrity, but evidence is limited by small human sample sizes and inconsistent replication. Most efficacy data come from observational studies or small RCTs rather than large, independently-replicated trials.

Exenatide demonstrates probable anti-inflammatory effects in humans based on multiple RCTs and observational studies, with measurable reductions in inflammatory markers (CRP, cytokines, protein clusters). However, evidence remains limited by small sample sizes, short treatment durations, and mixed findings across different inflammatory pathways.

Pemvidutide, a GLP-1/glucagon dual agonist, shows probable efficacy for reducing inflammation markers in humans with metabolic disease, but evidence is limited to a small number of human trials with modest sample sizes and indirect inflammation assessments. Direct anti-inflammatory effects have not been rigorously isolated from weight loss and metabolic improvements.

Survodutide shows probable anti-inflammatory effects in humans with metabolic diseases, with consistent reductions in inflammatory markers across multiple studies. However, evidence remains limited to a small number of human trials with modest sample sizes, and inflammation was typically a secondary outcome rather than the primary focus.

Thymopentin shows probable anti-inflammatory effects in human studies with multiple small-to-moderate RCTs and observational trials demonstrating reduced inflammatory markers and improved immune function, but evidence is limited by inconsistent study designs, small sample sizes, and lack of independent replication across diverse populations.

Calcium supplementation shows probable efficacy for reducing inflammation in specific clinical contexts, particularly preeclampsia prevention and postpartum immune function, but evidence is mixed and mostly limited to observational or small RCT designs with inconsistent effect sizes.

Vitamin B1 (thiamine) shows probable benefit for reducing inflammation and improving outcomes in sepsis, supported by multiple human studies with consistent positive findings. However, evidence is limited by small sample sizes, mixed results on specific outcomes, and lack of large-scale RCTs.

Vitamin B2 shows probable anti-inflammatory effects supported by one human RCT in Crohn's disease and multiple animal studies, but evidence remains limited by small sample sizes, short intervention periods, and lack of independent human replication.

Vitamin B3 (as nicotinamide and nicotinamide riboside) shows probable efficacy for reducing inflammation in humans, supported by multiple small-to-moderate RCTs and observational studies. Effects are meaningful but sample sizes are modest and results have not been independently replicated across all populations.

Folate supplementation shows probable efficacy for reducing inflammation markers, particularly C-reactive protein (CRP), in specific populations. However, evidence is limited by small sample sizes, inconsistent effects across different groups, and mixed results in some clinical contexts.

Ginger shows probable anti-inflammatory benefits in humans with joint pain and arthritis, supported by 3 human RCTs and multiple animal studies demonstrating consistent effects on inflammatory markers. However, human evidence is limited by small sample sizes and short study durations, preventing a higher tier rating.

Cinnamon shows probable efficacy for reducing inflammatory markers in humans, particularly C-reactive protein (CRP) and TNF-α in specific populations like rheumatoid arthritis. However, evidence is mixed across broader inflammation markers, with some studies showing null effects on CRP and other inflammatory biomarkers.

Lutein shows probable anti-inflammatory effects in humans, supported by multiple RCTs demonstrating reductions in specific inflammatory markers (complement factors, cytokines). However, evidence remains limited by small sample sizes, short durations, and inconsistent clinical outcomes across studies.

Zeaxanthin supplementation shows probable efficacy for reducing inflammatory markers in humans, with multiple RCTs demonstrating reductions in pro-inflammatory cytokines (IL-1β, TNF-α) and improvements in oxidative stress biomarkers. However, evidence is limited by small sample sizes, short durations, and inconsistent clinical outcome measures across studies.

Beetroot shows probable anti-inflammatory effects in human studies, with 3 RCTs demonstrating reductions in inflammatory markers and blood pressure. However, evidence is mixed—one RCT found no effect on inflammation biomarkers in healthy older adults—and human trials are small (n<100) with short durations (7 days to 4 weeks).

Vitamin A shows probable benefit for reducing inflammation in specific contexts (viral infections, severe illness), but evidence is mixed and often limited to biomarkers rather than clinical outcomes. Most human studies are observational or small RCTs without consistent, independently replicated efficacy.

Black pepper (piperine) combined with curcumin shows modest anti-inflammatory effects in multiple human RCTs, primarily reducing C-reactive protein and inflammatory markers in specific disease states. However, evidence is limited to small trials with inconsistent results, and efficacy for general inflammation reduction is not conclusively proven.

Moringa oleifera shows consistent anti-inflammatory effects in animal models and limited human studies, with reduced TNF-α and other inflammatory markers reported. However, evidence remains primarily from in-vitro and animal studies; human RCT data is minimal and results are mixed.

Caffeine shows probable anti-inflammatory effects in humans during and after exercise, with multiple RCTs demonstrating increased anti-inflammatory cytokines (IL-10) and reduced inflammatory markers in specific contexts. However, evidence is limited to acute exercise settings and cirrhosis populations; efficacy for general inflammation reduction in healthy populations remains unproven.

BPC-157 shows consistent anti-inflammatory and tissue-protective effects in extensive animal studies, with preliminary human pilot data suggesting potential efficacy. However, human evidence remains extremely limited with no controlled trials.

TB-500 shows consistent anti-inflammatory effects in multiple animal models and in vitro studies, but lacks human clinical trials demonstrating efficacy for inflammation reduction.

GHK-Cu shows consistent anti-inflammatory effects in animal models and cell culture, with emerging human observational data suggesting lower plasma GHK levels correlate with inflammatory diseases like COPD and asthma. However, no human RCTs exist, and efficacy in humans remains unproven.

Ipamorelin shows plausible anti-inflammatory and tissue-protective mechanisms in animal models, but there is no clinical evidence of efficacy for inflammation in humans. All direct evidence comes from rodent studies, with mechanism supported only by mechanistic review articles.

Semax suppresses proinflammatory gene expression in rodent stroke models, but efficacy is only demonstrated in animal studies. One human observational study exists but provides mechanistic insights only, not clinical outcome data.

Selank shows immunomodulatory and anti-inflammatory effects in multiple animal studies and a small number of human observational studies, but efficacy in humans remains unproven due to lack of RCTs and small sample sizes. Animal studies consistently demonstrate effects on inflammatory gene expression and cytokine balance, but clinical significance in human inflammation is not established.

Epithalon shows plausible anti-inflammatory effects in animal and cell culture studies through modulation of IL-2 and other immune markers, but no human clinical trials exist to prove efficacy for inflammation in humans.

DSIP has been studied in humans regarding HPA axis function and stress response, but direct evidence for anti-inflammatory efficacy is absent from these abstracts. Most findings relate to hormonal regulation rather than inflammation markers.

KPV demonstrates anti-inflammatory effects in multiple animal models and in vitro studies, but human efficacy evidence is limited to observational studies and mechanistic investigations. Clinical proof of efficacy in humans for inflammation is not yet established.

MOTS-c shows consistent anti-inflammatory effects in animal and limited human studies, with evidence suggesting it reduces inflammatory markers and protects against injury in multiple tissue types. However, efficacy in humans remains unproven—no randomized controlled trials exist, and the 7 human observational studies lack control groups and mechanistic confirmation.

SS-31 (Elamipretide) shows consistent anti-inflammatory effects in animal models and cell culture through mitochondrial stabilization and ROS reduction, but human efficacy for inflammation specifically remains unproven—only 2 human observational studies exist, neither directly measuring inflammatory outcomes as primary endpoints.

AOD-9604 shows plausible anti-inflammatory and cartilage-protective effects in an animal osteoarthritis model, but no human efficacy data exists. Evidence is limited to a single rabbit study and mechanistic review.

Sermorelin and GHRH agonists show anti-inflammatory effects in animal models and limited human studies, primarily through modulation of immune cell function and reduction of pro-inflammatory cytokines. However, robust human clinical evidence demonstrating efficacy for inflammation is lacking.

LL-37 shows anti-inflammatory effects primarily in animal models and cell culture studies, with emerging human observational evidence suggesting elevated LL-37 correlates with inflammatory conditions. However, no human RCTs demonstrate therapeutic efficacy for inflammation, and the role of LL-37 appears context-dependent—sometimes protective, sometimes pro-inflammatory.

Dihexa shows promise for reducing inflammation in animal models of Alzheimer's disease through modulation of the brain angiotensin/PI3K-AKT axis, but no human clinical trials have been conducted. Evidence is limited to one animal study and mechanistic reviews.

Kisspeptin shows plausible anti-inflammatory mechanisms in animal and in vitro models, but human efficacy for inflammation is not yet established. Two human RCTs exist, but neither directly measured inflammatory outcomes as a primary endpoint.

GHRP-2 shows anti-inflammatory effects in one rat model of acute lung injury and one in-vitro study of ovarian cells, but human evidence for anti-inflammatory efficacy is absent. All human studies examined GHRP-2's effects on growth hormone and cortisol secretion for diagnostic or metabolic purposes, not inflammation as a primary outcome.

GHRP-6 shows anti-inflammatory potential primarily through animal and mechanistic studies, with limited human evidence focused on HPA axis modulation rather than direct inflammatory markers. Efficacy in humans for inflammation reduction remains unproven.

Hexarelin demonstrates anti-inflammatory effects in cardiac models, reducing markers like TNF-α, IL-1β, and TGF-β1 in two mouse studies of myocardial injury. However, evidence for broad anti-inflammatory efficacy is limited to animal models; human studies focus on hormonal effects rather than inflammation outcomes.

Melanotan 2 shows consistent anti-inflammatory effects in animal models through melanocortin receptor activation, but no human trials have been conducted to confirm efficacy for inflammation in humans.

Gonadorelin (GnRH agonists) shows plausible anti-inflammatory effects in endometriosis-related conditions based on multiple human studies, but evidence of direct anti-inflammatory efficacy is indirect and primarily measured through surrogate markers rather than clinical inflammation outcomes.

Humanin shows anti-inflammatory effects in multiple animal and cell culture models, with one small human RCT demonstrating benefits when combined with exercise and astaxanthin. However, human efficacy for inflammation as a standalone intervention remains largely unproven.

Follistatin 344 shows plausible anti-inflammatory effects primarily through exercise-induced upregulation in human studies, but direct anti-inflammatory efficacy has not been independently proven in humans. Evidence is limited to observational associations with inflammatory markers during resistance training, with no RCTs specifically testing follistatin administration for inflammation.

GDF-11 shows consistent anti-inflammatory effects across multiple animal models and cell culture studies, with emerging evidence from observational human studies. However, no rigorous human RCTs have definitively proven efficacy for inflammation reduction in clinical populations.

FOXO4-DRI reduces cellular senescence and inflammatory markers in a rat model of bronchopulmonary dysplasia, but no human efficacy studies exist. Evidence is limited to one animal study and one review discussing the therapeutic potential of senolytic compounds.

VIP demonstrates anti-inflammatory mechanisms and immunoregulatory effects in preclinical and mechanistic studies, but human efficacy for reducing inflammation remains unproven. The single human RCT (apremilast in psoriasis) found no significant reduction in vascular inflammation despite addressing a VIP-related inflammatory pathway.

Pinealon shows promise for reducing neuroinflammation in animal models of acute hypoxia, but no human clinical trials exist. Evidence is limited to a single rat study demonstrating decreased inflammatory cytokines and neuroinflammatory responses.

Cortagen modulates immune cytokine production (IL-2 and lymphocyte-activating factors) in animal models, but efficacy for inflammation is not proven in humans. All evidence comes from rodent studies with no human clinical trials.

Vilon shows plausible anti-inflammatory effects in animal and cell culture models through modulation of cytokine expression and immune cell function, but no human clinical trials exist to prove efficacy in humans.

Bronchogen shows consistent anti-inflammatory effects in rat models of chronic obstructive pulmonary disease, with evidence of reduced neutrophilic inflammation and restored bronchial epithelial function. However, no human clinical trials exist, limiting proof of efficacy to animal studies only.

MGF shows promise for reducing inflammation in animal models and in vitro systems, with plausible anti-inflammatory mechanisms demonstrated across multiple studies. However, human efficacy for inflammation remains unproven—only 1 human RCT exists (on muscle damage, not inflammation as primary outcome) and 4 observational studies in disease-specific contexts without rigorous inflammation measurement.

Oxytocin shows anti-inflammatory and anxiolytic effects in animal models of neuroinflammation, but evidence is limited to preclinical research with only one small human observational study. Efficacy in humans for inflammation remains unproven.

NMN shows anti-inflammatory effects in animal models and limited human studies, with mechanistic plausibility through NAD+ restoration and SIRT1 pathway activation. However, human efficacy is not yet proven—only 2 human RCTs exist, one showing mixed results (suppressed some inflammatory markers but impaired mitochondrial adaptation), and the other in a specialized cancer context.

Tongkat Ali shows consistent anti-inflammatory effects in cell and animal studies through NF-κB and nitric oxide inhibition, but evidence for clinical efficacy in inflammation is limited to one small human RCT examining menopausal symptoms with modest results.

Milk thistle (silymarin) demonstrates anti-inflammatory and antioxidant properties in mechanistic and animal studies, with limited human evidence for inflammation reduction. Only 2 human RCTs were identified, one showing no significant benefit for NASH and another showing microbiota and cytokine improvements in a nutraceutical blend containing silymarin.

Maca shows anti-inflammatory effects in cell-based and animal studies, with emerging evidence suggesting reduced inflammatory markers in a small human observational study. However, only one human RCT exists (n=29), which found no significant changes in serum cytokines despite improvements in blood pressure and depression.

Elderberry shows anti-inflammatory effects in in-vitro and animal studies with a plausible mechanistic basis, but evidence from human trials is minimal and inconsistent. One small RCT (n=24) showed only a trend toward cognitive improvement without statistical significance in inflammatory markers.

Green tea extract (EGCG) shows consistent anti-inflammatory effects in animal models and limited human in-vitro studies, but human clinical efficacy remains largely unproven. Only 1 human RCT exists in these abstracts, and it was conducted in rats despite being labeled as such.

Psyllium husk shows promise for reducing inflammation in animal models and in vitro studies, with one human RCT demonstrating efficacy for laryngopharyngeal reflux-related inflammation. However, human evidence is limited and mixed: large RCTs found no effect on systemic inflammatory markers (CRP, IL-6), limiting proof of efficacy for general inflammation.

B vitamins show plausible anti-inflammatory effects across multiple observational studies and mechanistic reviews, but human RCT evidence for inflammation reduction is limited and inconsistent. Most evidence comes from observational data, mechanistic studies, or secondary outcomes in trials focused on other conditions.

Iron supplementation is studied primarily for treating anemia of inflammation and iron deficiency anemia, not for reducing inflammation itself. Evidence shows iron's complex relationship with inflammation: while iron is necessary for treating inflammatory anemia, excess iron can paradoxically worsen inflammation and cellular damage in inflammatory conditions.

Iodine's relationship with inflammation is complex and bidirectional: both deficiency and excess iodine can trigger autoimmune thyroid inflammation, but no human RCTs demonstrate iodine supplementation reduces inflammation as a primary outcome. Evidence is largely mechanistic and observational.

Copper shows plausible anti-inflammatory mechanisms in animal and cell studies, with some human observational evidence suggesting complex relationships between copper status and inflammatory markers. However, no rigorous human RCTs demonstrate clinically meaningful efficacy for inflammation reduction.

Fisetin shows consistent anti-inflammatory effects in animal models and cell culture through NF-κB and MAPK pathway inhibition, with emerging human observational evidence suggesting senolytic and anti-inflammatory benefits. However, no human RCTs exist, and all efficacy claims remain unproven in clinical populations.

DIM shows anti-inflammatory activity in animal and cell culture models, primarily through NF-κB pathway suppression, but human evidence is limited to one small pilot study (n=19) focused on estrogen metabolites rather than inflammatory outcomes. Efficacy for inflammation in humans remains unproven.

Nattokinase shows anti-inflammatory effects in animal models and some human observational studies, but robust clinical efficacy for inflammation is not yet proven. A large human RCT found no significant effects on cardiovascular biomarkers.

Shilajit demonstrates anti-inflammatory properties in animal models and mechanistic studies, but efficacy in humans for inflammation is supported by only one RCT as part of a multi-ingredient intervention, making human proof of efficacy limited and inconclusive.

Colostrum shows plausible anti-inflammatory mechanisms in preclinical and neonatal studies, but human evidence of efficacy for inflammation reduction is limited to small, short-term trials with mixed results and no consistent clinically meaningful improvements.

Turkey Tail mushroom polysaccharides (PSK/PSP) activate immune cells and inflammatory pathways in laboratory and animal studies, but no human clinical trials demonstrate efficacy for reducing inflammation. Evidence is limited to mechanistic studies in cells and animal models.

Chaga mushroom shows consistent anti-inflammatory effects in cell and animal models, with one human RCT suggesting potential benefits as part of a multi-ingredient supplement. However, efficacy in humans for inflammation specifically remains unproven, with only limited human data and no dedicated human inflammation trials.

Epicatechin shows consistent anti-inflammatory effects across multiple in-vitro and animal studies, with one human observational study demonstrating efficacy in preeclampsia-related inflammation. However, no rigorous human RCTs exist, limiting definitive proof of clinical efficacy for inflammation in the general population.

Apigenin shows consistent anti-inflammatory effects across multiple animal models of colitis, necrotic enteritis, and vascular/neuroinflammation, but evidence in humans is limited to one small observational study associating dietary apigenin with sleep quality. Efficacy is plausible but not proven in human populations for inflammation.

Olive leaf extract shows anti-inflammatory effects in multiple animal and cell culture studies, with a few small human observational studies suggesting potential benefits. However, human efficacy remains unproven—only 1 human RCT exists, and recent meta-analyses of clinical trials found inconsistent or non-significant effects on inflammatory markers.

Stinging nettle shows anti-inflammatory effects in animal models and in vitro studies, with one small human RCT demonstrating modest benefits for allergic rhinitis symptoms. However, efficacy in humans remains largely unproven, with only a single small RCT available and most evidence derived from preclinical models.

Mucuna pruriens shows anti-inflammatory activity in multiple animal and in-vitro studies, but lacks human clinical trials demonstrating efficacy for inflammation management. Evidence is promising but not yet proven in humans.

Ecdysterone shows promising anti-inflammatory effects in animal models and cell cultures through multiple mechanisms (NF-κB inhibition, SIRT6 activation, pyroptosis suppression), but lacks rigorous human clinical trials. Current evidence is insufficient to prove clinical efficacy in humans for inflammation.

Cistanche shows consistent anti-inflammatory effects in cell culture and animal models through multiple molecular pathways, but human evidence is limited to a single small RCT on hair health and one observational study on sepsis. Efficacy for inflammation is plausible but not yet proven in human populations.

Valerian root shows plausible anti-inflammatory mechanisms in cell culture and animal models, but human evidence for inflammation reduction is extremely limited. Only one small human RCT exists, focused on cognitive outcomes rather than direct inflammatory markers.

Kava shows anti-inflammatory effects in multiple animal models through TNF-α suppression and reduced osteoclastogenesis, but efficacy in humans remains unproven. One human case report documents kava dermopathy (an inflammatory adverse effect), not therapeutic benefit for inflammation.

Passionflower shows plausible anti-inflammatory mechanisms in preclinical and observational studies, but direct evidence of inflammation reduction in humans is absent. Most human data focuses on anxiety and stress rather than inflammatory markers.

Schisandra chinensis shows consistent anti-inflammatory effects in animal models and in-vitro studies through multiple mechanisms (NF-κB inhibition, NLRP3 inflammasome suppression, cytokine reduction), but human efficacy for inflammation is supported by only 3 small RCTs with limited sample sizes and no independent replication.

CLA shows mixed effects on inflammation in humans, with some evidence of decreased IL-6 and TNF-α but paradoxically increased CRP levels. Only 1 human RCT exists; most evidence comes from animal models and meta-analyses of small studies.

Lithium orotate is studied primarily for neuroprotection and anti-inflammatory effects in animal models and in-vitro systems, but no human clinical trials exist demonstrating efficacy for inflammation. Evidence is limited to mechanistic studies and animal models showing promise.

Pregnenolone shows plausible anti-inflammatory potential based on mechanistic studies and observational data, but lacks rigorous human RCT evidence demonstrating direct efficacy for inflammation. Most evidence is correlational or from animal models.

SAMe shows mechanistic promise for reducing inflammation through multiple pathways (interferon signaling, methylation, antioxidant support), but human efficacy for inflammation specifically remains largely unproven. One double-blind RCT showed SAMe was comparable to celecoxib for osteoarthritis pain, but most evidence comes from mechanistic studies, observational data, and animal models.

Whey protein supplementation shows mixed and largely inconsistent effects on inflammatory markers in humans. Meta-analyses report no significant effects on overall inflammation, though some individual RCTs found modest reductions in specific cytokines like IL-6 in particular populations.

Forskolin shows consistent anti-inflammatory effects in animal models and cell cultures through cAMP-dependent mechanisms, but no human RCTs or clinical trials exist to prove efficacy for inflammation in humans.

Betaine shows plausible anti-inflammatory effects based on mechanistic understanding and animal studies, but human evidence is limited and inconsistent. A 2023 meta-analysis of 6 RCTs found only marginal reductions in IL-1β and no significant effects on CRP, IL-6, or TNF-α, failing to establish proven efficacy for inflammation in humans.

Lion's Mane demonstrates anti-inflammatory effects in laboratory and animal models with plausible mechanisms, but human efficacy for inflammation remains unproven. Only one small human RCT exists (cognitive outcomes, not inflammation-specific), and clinical anti-inflammatory benefits have not been established in humans.

Alpha-GPC shows consistent anti-inflammatory effects in animal models and limited human observational data, but lacks rigorous human RCT evidence for inflammation specifically. Most human studies focus on cognition rather than inflammation as a primary endpoint.

Bacopa monnieri shows anti-inflammatory effects in cellular and animal models with proposed mechanisms targeting NF-κB and pro-inflammatory cytokines, but human evidence for inflammation reduction remains limited to 2 small RCTs with mixed or indirect results.

Phosphatidylserine (PS) is involved in multiple inflammatory pathways based on mechanistic studies, but there is no human evidence demonstrating that PS supplementation reduces inflammation. The evidence consists primarily of observational studies identifying PS as a biomarker or mechanism in disease states, and animal models showing PS-targeted interventions modulate immune responses.

CDP-choline has demonstrated anti-inflammatory effects in multiple animal models and a few small human studies, but robust clinical evidence in humans for inflammation reduction remains limited. Most evidence comes from animal studies or mechanistic reviews rather than large, well-controlled human trials.

Panax ginseng and its ginsenosides show consistent anti-inflammatory effects in animal models and in vitro studies through multiple molecular pathways (NF-κB, MAPK, oxidative stress reduction), but human evidence is limited to one observational study on asthma. Efficacy in humans remains plausible but unproven.

Huperzine A shows consistent anti-inflammatory effects in animal models of inflammatory disease (myocardial infarction, cerebral ischemia, sepsis-induced lung injury) and in vitro in microglial cells, but evidence for efficacy in humans is limited to observational studies in cognitive decline without direct inflammation outcome measures. The anti-inflammatory mechanism is well-characterized, but clinical proof of efficacy for inflammation as a primary outcome in humans is lacking.

PQQ demonstrates consistent anti-inflammatory effects in animal models and cell culture through multiple mechanistic pathways (NF-κB, JAK-STAT, SIRT1), but human efficacy evidence is extremely limited with only one small RCT (n=10) showing reduced C-reactive protein and IL-6 levels after 76 hours of supplementation.

Noopept demonstrates anti-inflammatory effects in multiple rodent models, but no human trials exist. Efficacy is plausible based on consistent animal findings, but proof in humans is absent.

Piracetam shows anti-inflammatory effects in animal models of stroke and chemotherapy-induced toxicity, but human evidence for inflammation-related benefits is extremely limited. Most evidence is mechanistic or from animal studies; clinical efficacy in humans for inflammation reduction remains unproven.

Aniracetam shows promise for reducing inflammation in preclinical stroke models through AMPA receptor modulation and cytokine regulation, but evidence is limited to a single human RCT in stroke recovery with indirect inflammation markers. Efficacy for inflammation as a primary goal in humans remains unproven.

Phenylpiracetam shows anti-inflammatory effects in animal models, but no human clinical trials have been conducted to date. Evidence is limited to rodent studies and mechanistic reviews, making efficacy in humans unproven.

Uridine supplementation has been studied for inflammation primarily through its role in pyrimidine metabolism and mitochondrial function, but direct anti-inflammatory efficacy in humans is not conclusively demonstrated. Most evidence is mechanistic or from animal/cell studies; the few human trials show mixed or modest results.

9-ME-BC shows anti-inflammatory effects and neuroprotection in cell culture and animal models, with consistent mechanistic findings across studies. However, no human clinical trials exist, leaving efficacy in humans unproven.

Bromantane (ladasten) shows promise for reducing pro-inflammatory cytokines in animal models of depression and stress, but efficacy in humans for inflammation is not proven. Only one human study exists, focused on fatigue rather than inflammation markers.

Sulbutiamine shows anti-inflammatory effects in animal models of diabetic nephropathy and in cellular systems through modulation of NF-κB and oxidative stress pathways. However, no human clinical trials exist to confirm efficacy for inflammation in humans.

L-theanine shows plausible anti-inflammatory effects in animal models and preliminary human studies, but efficacy in humans for inflammation specifically is not yet proven. Most evidence derives from animal studies or mechanistic reviews rather than human clinical trials.

L-Glutamine shows plausible anti-inflammatory effects primarily in animal models and mechanistic studies, with limited human evidence. One meta-analysis found modest CRP reduction in critically ill patients, but broader inflammatory markers (IL-6, TNF-α) showed no significant benefit.

5-HTP shows plausible anti-inflammatory effects in animal models and mechanistic human studies, but lacks direct human RCT evidence demonstrating efficacy for inflammation reduction. Most human data focus on neuroendocrine responses rather than inflammatory outcomes.

GABA demonstrates anti-inflammatory effects in animal models and in vitro systems through modulation of key signaling pathways (NF-κB, NLRP3), but human evidence for efficacy in inflammation is limited to 4 observational studies with no RCTs, making efficacy plausible but not proven in humans.

L-Citrulline's anti-inflammatory effects are plausible based on mechanism studies and animal research, but human evidence for inflammation reduction is minimal and inconsistent. The largest human meta-analysis (2023) found no significant effects on inflammatory biomarkers in response to exercise.

BCAAs show mixed effects on inflammation with concerning recent findings. While some exercise studies report reduced inflammatory markers, multiple recent human studies demonstrate that BCAA supplementation actually promotes pro-inflammatory responses and worsens metabolic inflammation, particularly in obesity and cardiovascular disease contexts.

L-Arginine supplementation does not consistently reduce inflammatory markers (CRP, TNF-α, IL-6) in human studies, and may paradoxically increase CRP in older adults and certain patient populations. While mechanistic pathways through the arginine/nitric oxide pathway are well-characterized, clinical efficacy for inflammation reduction remains unproven.

Leucine supplementation shows plausible anti-inflammatory effects in animal models and limited human studies, but efficacy for inflammation reduction in humans remains unproven. Most evidence comes from animal studies or mechanistic observations rather than confirmed clinical benefit.

Tryptophan supplementation shows plausible anti-inflammatory effects through activation of the aryl hydrocarbon receptor (AhR) and modulation of the tryptophan-kynurenine pathway in humans, but efficacy for reducing inflammation is not yet proven. Evidence is limited to mechanistic studies and small observational trials; no large-scale RCTs demonstrate clinical anti-inflammatory benefit.

One small human RCT (n=52) found that L-ornithine 400 mg/day reduced cortisol levels and improved sleep quality in healthy workers with mild stress. However, a single study is insufficient to prove efficacy for inflammation specifically, and the study did not directly measure inflammatory markers.

L-lysine shows plausible anti-inflammatory effects in animal models of IBS and autoimmune hepatitis, with demonstrated improvements in barrier function and immune markers. However, no human clinical trials exist, so efficacy in humans remains unproven.

Cortistatin shows potent anti-inflammatory effects in animal models and limited human observational studies, but lacks rigorous human RCTs to prove clinical efficacy. Evidence is emerging but not yet confirmed in humans.

Ghrelin shows mechanistic links to inflammation through multiple pathways, but direct evidence that ghrelin supplementation reduces inflammation in humans is absent. Existing human studies focus on ghrelin's role in appetite and metabolism rather than inflammatory outcomes.

Linaclotide shows anti-inflammatory effects in multiple animal models and mechanistic studies, but evidence in humans is limited to observational studies and reviews. Efficacy for inflammation is plausible but not yet proven in rigorous human trials.

Lixisenatide shows consistent anti-inflammatory effects across multiple in-vitro and animal models, reducing oxidative stress, inflammatory cytokines, and inflammatory markers. However, no human RCTs or observational studies specifically measuring inflammatory outcomes have been published—evidence of efficacy in humans is lacking.

Matrixyl (palmitoyl pentapeptide-4 and related peptides) shows promise for reducing inflammation in animal wound and photoaging models, but no human studies have tested this compound for inflammation specifically.

NA-Semax Amidate accelerated ulcer healing and reduced inflammation in rats, but no human trials exist. Efficacy in humans remains unproven.

Nesfatin-1 levels correlate with inflammatory markers in various diseases, but evidence for nesfatin-1 as a therapeutic intervention to reduce inflammation is absent. Studies demonstrate associations between elevated nesfatin-1 and inflammatory conditions, but causality and therapeutic efficacy remain unproven.

Neuropeptide Y shows anti-inflammatory effects across multiple animal models and in vitro systems, with mechanistic evidence suggesting Y1 and Y2 receptor involvement. However, human evidence for inflammation is limited to observational studies and one small RCT, with no large-scale human trials demonstrating efficacy.

Octreotide shows plausible anti-inflammatory effects across multiple animal models and limited human studies, but lacks robust human RCT evidence demonstrating clear efficacy for inflammation reduction.

Orexin-A shows consistent anti-inflammatory effects in animal models of brain injury and neuroinflammation, with plausible mechanisms via NF-κB and NLRP3 pathways. However, no human RCTs have demonstrated efficacy for inflammation, and human observational data do not support a primary anti-inflammatory role.

P21 shows consistent anti-inflammatory effects in animal models of neuroinflammation and cellular senescence, but no human trials have tested whether P21 supplementation or peptide mimetics actually reduce inflammation in people. Evidence is mechanistic and preclinical only.

PACAP-38 shows anti-inflammatory properties in preclinical and observational studies, but there is only 1 small human RCT with cardiac outcomes, not inflammation-specific endpoints. Efficacy for inflammation in humans remains unproven.

Peptide YY shows associations with inflammatory markers and plays a role in gut barrier function in mechanistic studies, but direct evidence that raising PYY levels reduces inflammation in humans is lacking. Most evidence is observational or from animal models.

Pramlintide shows promise for reducing inflammatory markers in cell studies and may have anti-inflammatory effects in endothelial cells, but human efficacy for inflammation is not proven. The evidence is primarily mechanistic (cell-based and animal studies) with no dedicated human RCTs demonstrating clinical anti-inflammatory benefit.

Setmelanotide shows anti-inflammatory effects in animal and cellular models, and one case report documents resolution of chronic urticaria in a patient with Bardet-Biedl Syndrome, but no human RCTs or large observational studies have directly tested efficacy for inflammation as a primary outcome.

Teriparatide (PTH1-34) shows promise for reducing inflammation in preclinical models and may help manage osteoporosis-related bone loss, but evidence for direct anti-inflammatory effects in humans is limited to mechanistic studies and observational data. No rigorous human RCTs demonstrate that teriparatide reduces systemic inflammation as a primary outcome.

Thymulin shows anti-inflammatory effects in animal models of inflammatory pain and lung disease, but human evidence is limited to observational studies of immune markers with no RCTs demonstrating clinical efficacy for inflammation.

NAD+ shows promise for reducing inflammation in animal models and early human studies, but human evidence remains limited to one small RCT and observational studies. Efficacy in humans is plausible but not yet proven.

CAAKG (calcium alpha-ketoglutarate) shows promise for reducing inflammation based on mechanistic studies and limited animal evidence, but lacks adequate human RCT data to prove efficacy. Most evidence is observational, mechanistic, or animal-based.

Manganese shows promise for reducing inflammation markers in diabetes-related endothelial dysfunction, but evidence is limited to one human cell culture study and animal models. No human clinical trials demonstrate efficacy for inflammation.

Vitamin B5 (pantothenic acid) shows anti-inflammatory effects in animal models, reducing inflammatory cytokines and endometrial injury through multiple mechanisms. However, no human studies exist to confirm efficacy in reducing inflammation in people.

Vitamin B6 shows anti-inflammatory effects in cell and animal studies, but human evidence for treating inflammation is weak and inconsistent. One human RCT found B6 supplementation did NOT improve inflammatory markers in rheumatoid arthritis patients despite correcting deficiency.

Luteolin shows consistent anti-inflammatory effects in animal models and cell studies through well-characterized molecular pathways (NF-κB, MAPK, TLR inhibition), but human efficacy remains unproven—only 2 small human observational studies exist with no randomized controlled trials demonstrating clinical benefit for inflammation.

Lecithin shows promise for reducing inflammation in animal studies and one small human trial, but human evidence for anti-inflammatory efficacy is extremely limited and inconclusive. The single human RCT did not report complete inflammatory outcomes.

Vitamin K1 shows potential anti-inflammatory mechanisms in human studies, but clinical efficacy for reducing inflammation is not proven. Two RCTs in rheumatoid arthritis patients found no significant effects on inflammatory markers after adjusting for confounders, despite some raw improvements.

Lycopene has anti-inflammatory properties demonstrated in mechanistic studies and animal models, but human evidence for inflammation reduction is weak and inconsistent. Most intervention studies in humans show increased circulating lycopene without corresponding improvements in inflammation biomarkers.

MCT oil shows plausible anti-inflammatory potential based on mechanistic studies and limited human evidence, but efficacy in humans for inflammation reduction has not been definitively proven. Most evidence comes from animal models, parenteral nutrition contexts, or mechanistic reviews rather than targeted human trials testing MCT oil's anti-inflammatory effects.

Burdock extract (as part of a multi-ingredient blend) reduced inflammation markers in cell cultures and improved periodontal outcomes in rats, but no human studies exist to confirm efficacy in people.

Sea moss extract contains anti-inflammatory compounds (polysaccharides, omega-3 fatty acids, phenolics) that show promise in animal and cell culture models, but there are zero human clinical trials demonstrating efficacy for inflammation. Evidence is limited to laboratory and animal studies.

Dandelion root extract shows anti-inflammatory effects in animal models of colitis and intestinal injury, but there are zero human clinical trials. Evidence is limited to rodent studies and in-vitro work.

Yellow Dock (Rumex species) shows consistent anti-inflammatory effects in animal models and in-vitro studies, with identified active compounds like emodin and nepodin demonstrating COX inhibition. However, no human clinical trials exist, so efficacy in humans remains unproven.

Chlorophyll shows promise for reducing inflammation in animal models, but there is no human evidence demonstrating efficacy for inflammation. All evidence comes from rodent studies or laboratory cell experiments.

Slippery elm shows promise for modulating gut microbiota and enhancing immune markers in preliminary studies, but efficacy for inflammation in humans remains unproven. Only one human RCT exists, and it measured microbiota changes rather than direct anti-inflammatory outcomes.

DHEA shows associations with reduced inflammation markers (lower CRP, IL-6) and improved inflammatory profiles in observational studies, but human RCT evidence is minimal and does not directly demonstrate that DHEA supplementation reduces inflammation. Most evidence is correlational or mechanistic rather than demonstrating proven clinical efficacy.

CJC-1295 is mentioned as a growth hormone secretagogue with theoretical anti-inflammatory potential through IGF-1 signaling, but no human or animal studies specifically demonstrating efficacy for inflammation are presented in these abstracts.

PT-141 is not directly studied for inflammation in the available literature. A single 2025 review discusses melanocortin receptors (which PT-141 acts upon) and their theoretical involvement in inflammatory diseases, but provides no clinical efficacy data for PT-141 itself.

Cardiogen has not been demonstrated to reduce inflammation in humans. The only human data is an incidental case report unrelated to inflammation, while in-vitro data shows it may influence fibroblast signaling markers in aging cultures, but this is not evidence of anti-inflammatory efficacy.

Chonluten shows anti-inflammatory effects in cultured human monocyte cells exposed to bacterial lipopolysaccharide, but there is only one in-vitro study and no human clinical trials demonstrating efficacy for inflammation.

Cartalax has only in-vitro evidence showing modulation of aging-related gene expression in human mesenchymal stem cells. No human efficacy data exists for inflammation, and in-vitro gene expression changes do not demonstrate clinical anti-inflammatory effects.

IGF-1 LR3 has not been studied for its direct anti-inflammatory effects. The two available abstracts examine IGF-1 LR3 only as a co-factor in reproductive and lactation contexts, with no investigation of inflammation as a primary outcome.

Argireline (acetyl hexapeptide-8) shows anti-inflammatory activity in zebrafish embryos and in-vitro fibroblast models, but there are no human clinical trials demonstrating efficacy for inflammation. All evidence is derived from non-human systems.

Only a single review article discusses turkesterone's anti-inflammatory potential through cell culture data from Ajuga plants; no human efficacy studies exist for turkesterone and inflammation.

No human or animal efficacy studies exist for Fadogia agrestis and inflammation. Only a chemical analysis method paper is available, which documents the presence of phenolic compounds but provides no evidence that the supplement actually reduces inflammation.

D-Ribose has not been directly studied for inflammation in humans. The 48 abstracts discuss ribose metabolism in immune cells and cellular energy pathways, but none demonstrate that D-Ribose supplementation reduces inflammatory markers or improves inflammatory conditions.

Centrophenoxine has not been demonstrated to have proven efficacy for inflammation in humans. The only relevant finding is a single in-vitro study showing an 8.8% increase in neutrophil phagocytosis at high drug concentrations, which is neither clinically meaningful nor specific to inflammation reduction.

NSI-189 has not been studied for inflammation specifically in the available PubMed literature. The single identified study examined cognitive dysfunction in irradiated rats, with no direct measurement or reporting of inflammatory outcomes.

No evidence supports pramiracetam's efficacy for inflammation. The single available study examined memory enhancement in the context of corticosteroid interference, not inflammatory markers or inflammation-related outcomes.

L-Serine for inflammation has not been directly studied in any of the 50 identified abstracts. The abstracts mention serine as an amino acid component in foods (clove) and describe serine endopeptidase (nattokinase) mechanisms, but do not evaluate L-Serine supplementation as an anti-inflammatory agent.

Abaloparatide has not been studied for reducing inflammation in humans. All evidence of anti-inflammatory effects comes from animal studies and mechanistic research, with no clinical trials demonstrating benefit for inflammatory conditions.

Adipotide is not directly studied in any of these abstracts for inflammation. The three papers discuss prohibitin-targeting peptides, estrogen receptor agonists, and ovarian cancer biomarkers—none focus on adipotide or demonstrate its efficacy for reducing inflammation.

No human evidence demonstrates that cagrilintide reduces inflammation. Both available abstracts are reviews that discuss cagrilintide in the context of obesity and diabetes treatment, but neither provides data on inflammatory outcomes.

IGF-1 DES has not been shown to reduce inflammation in humans. The only relevant study found modest effects on inflammatory gene expression in cultured cancer cells, not in living organisms.

Lanreotide has not been demonstrated to effectively treat inflammation. The available evidence shows lanreotide used as an adjunct in cancer treatment and for neuroendocrine tumor management, with immune modulation observed as a secondary effect, but no studies directly assess lanreotide for inflammation as a primary outcome.

Vosoritide (BMN-111) has not been studied for inflammation in humans. A single animal study found that vosoritide treatment increased markers of bone turnover in mice but did not improve bone mass—findings inconsistent with the drug's mechanism and irrelevant to inflammation.

C-10 (3-oxo-C10-HSL, a bacterial quorum sensing molecule) has been studied only in laboratory cell cultures and animal models for inflammation. No human clinical trials exist demonstrating efficacy in reducing inflammation.

Kelp has been studied in animals and reviewed in general herb-drug interaction literature, but there is no human evidence demonstrating that kelp reduces inflammation. Studies focus on other outcomes like thyroid function, kidney health in viral infection, and safety profiles.

Only in-vitro laboratory data exists for Manuka honey and inflammation; no human studies demonstrate efficacy for reducing inflammation in any clinical setting.

Custom orthotic inserts are mentioned in one literature review as improving biomechanical alignment and outperforming off-the-shelf alternatives for heel pain, but no evidence directly demonstrates that custom orthotics reduce inflammation as a primary outcome.